Selected research
Industry Research
Management of Antithrombin Industry Research Report 2026
Market perspective
The global Management of Antithrombin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Management of Antithrombin market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Management of Antithrombin market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Management of Antithrombin market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Management of Antithrombin include Takeda, Grifols, Scripps Laboratories Inc., rEVO Biologics Inc., Lee Biosolutions, Kedrion S.p.A. and CSL Limited, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Management of Antithrombin market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Management of Antithrombin.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Management of Antithrombin Market by Company
Takeda
Grifols
Scripps Laboratories Inc.
rEVO Biologics Inc.
Lee Biosolutions
Kedrion S.p.A.
CSL Limited
Management of Antithrombin Segment by Type
Liquid
Lyophilized
Management of Antithrombin Segment by Application
Diagnostics
Therapeutics
Research
Management of Antithrombin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Management of Antithrombin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Management of Antithrombin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Management of Antithrombin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Management of Antithrombin companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Liquid
- Lyophilized
Applications
- Diagnostics
- Therapeutics
- Research
Companies covered
- Takeda
- Grifols
- Scripps Laboratories Inc.
- rEVO Biologics Inc.
- Lee Biosolutions
- Kedrion S.p.A.
- CSL Limited
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Management of Antithrombin by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Liquid
- 2.2.3 Lyophilized
- 2.3 Management of Antithrombin by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Diagnostics
- 2.3.3 Therapeutics
- 2.3.4 Research
- 2.4 Assumptions and Limitations
3 Management of Antithrombin Breakdown Data by Type
- 3.1 Global Management of Antithrombin Historic Market Size by Type (2021-2026)
- 3.2 Global Management of Antithrombin Forecasted Market Size by Type (2027-2032)
4 Management of Antithrombin Breakdown Data by Application
- 4.1 Global Management of Antithrombin Historic Market Size by Application (2021-2026)
- 4.2 Global Management of Antithrombin Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Management of Antithrombin Market Perspective (2021-2032)
- 5.2 Global Management of Antithrombin Growth Trends by Region
- 5.2.1 Global Management of Antithrombin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Management of Antithrombin Historic Market Size by Region (2021-2026)
- 5.2.3 Management of Antithrombin Forecasted Market Size by Region (2027-2032)
- 5.3 Management of Antithrombin Market Dynamics
- 5.3.1 Management of Antithrombin Industry Trends
- 5.3.2 Management of Antithrombin Market Drivers
- 5.3.3 Management of Antithrombin Market Challenges
- 5.3.4 Management of Antithrombin Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Management of Antithrombin Players by Revenue
- 6.1.1 Global Top Management of Antithrombin Players by Revenue (2021-2026)
- 6.1.2 Global Management of Antithrombin Revenue Market Share by Players (2021-2026)
- 6.2 Global Management of Antithrombin Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Management of Antithrombin Head Office and Area Served
- 6.4 Global Management of Antithrombin Players, Product Type & Application
- 6.5 Global Management of Antithrombin Manufacturers Established Date
- 6.6 Global Management of Antithrombin Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Management of Antithrombin Market Size (2021-2032)
- 7.2 North America Management of Antithrombin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Management of Antithrombin Market Size by Country (2021-2026)
- 7.4 North America Management of Antithrombin Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Management of Antithrombin Market Size (2021-2032)
- 8.2 Europe Management of Antithrombin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Management of Antithrombin Market Size by Country (2021-2026)
- 8.4 Europe Management of Antithrombin Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Management of Antithrombin Market Size (2021-2032)
- 9.2 Asia-Pacific Management of Antithrombin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Management of Antithrombin Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Management of Antithrombin Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Management of Antithrombin Market Size (2021-2032)
- 10.2 South America Management of Antithrombin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Management of Antithrombin Market Size by Country (2021-2026)
- 10.4 South America Management of Antithrombin Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Management of Antithrombin Market Size (2021-2032)
- 11.2 Middle East & Africa Management of Antithrombin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Management of Antithrombin Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Management of Antithrombin Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda
- 12.1.1 Takeda Company Information
- 12.1.2 Takeda Business Overview
- 12.1.3 Takeda Revenue in Management of Antithrombin Business (2021-2026)
- 12.1.4 Takeda Management of Antithrombin Product Portfolio
- 12.1.5 Takeda Recent Developments
- 12.2 Grifols
- 12.2.1 Grifols Company Information
- 12.2.2 Grifols Business Overview
- 12.2.3 Grifols Revenue in Management of Antithrombin Business (2021-2026)
- 12.2.4 Grifols Management of Antithrombin Product Portfolio
- 12.2.5 Grifols Recent Developments
- 12.3 Scripps Laboratories Inc.
- 12.3.1 Scripps Laboratories Inc. Company Information
- 12.3.2 Scripps Laboratories Inc. Business Overview
- 12.3.3 Scripps Laboratories Inc. Revenue in Management of Antithrombin Business (2021-2026)
- 12.3.4 Scripps Laboratories Inc. Management of Antithrombin Product Portfolio
- 12.3.5 Scripps Laboratories Inc. Recent Developments
- 12.4 rEVO Biologics Inc.
- 12.4.1 rEVO Biologics Inc. Company Information
- 12.4.2 rEVO Biologics Inc. Business Overview
- 12.4.3 rEVO Biologics Inc. Revenue in Management of Antithrombin Business (2021-2026)
- 12.4.4 rEVO Biologics Inc. Management of Antithrombin Product Portfolio
- 12.4.5 rEVO Biologics Inc. Recent Developments
- 12.5 Lee Biosolutions
- 12.5.1 Lee Biosolutions Company Information
- 12.5.2 Lee Biosolutions Business Overview
- 12.5.3 Lee Biosolutions Revenue in Management of Antithrombin Business (2021-2026)
- 12.5.4 Lee Biosolutions Management of Antithrombin Product Portfolio
- 12.5.5 Lee Biosolutions Recent Developments
- 12.6 Kedrion S.p.A.
- 12.6.1 Kedrion S.p.A. Company Information
- 12.6.2 Kedrion S.p.A. Business Overview
- 12.6.3 Kedrion S.p.A. Revenue in Management of Antithrombin Business (2021-2026)
- 12.6.4 Kedrion S.p.A. Management of Antithrombin Product Portfolio
- 12.6.5 Kedrion S.p.A. Recent Developments
- 12.7 CSL Limited
- 12.7.1 CSL Limited Company Information
- 12.7.2 CSL Limited Business Overview
- 12.7.3 CSL Limited Revenue in Management of Antithrombin Business (2021-2026)
- 12.7.4 CSL Limited Management of Antithrombin Product Portfolio
- 12.7.5 CSL Limited Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst